Your browser doesn't support javascript.
loading
Temporal muscle thickness and survival in patients with amyotrophic lateral sclerosis.
Vinciguerra, Claudia; Toriello, Antonella; Nardone, Valerio; Romano, Daniele; Tartaglione, Salvatore; Abate, Filomena; Landolfi, Annamaria; Barone, Paolo.
Afiliación
  • Vinciguerra C; Neurology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Toriello A; Neurology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Nardone V; Department of Precision Medicine, University of Campania L.Vanvitelli, Napoli, Italy.
  • Romano D; Department of Neuroradiology, "San Giovanni di Dio e Ruggi d'Aragona" Hospital, Salerno, Italy.
  • Tartaglione S; Department of Neuroradiology, "San Giovanni di Dio e Ruggi d'Aragona" Hospital, Salerno, Italy.
  • Abate F; Neurology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Landolfi A; Neurology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Barone P; Neurology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Neurol Res ; 44(11): 1006-1010, 2022 Nov.
Article en En | MEDLINE | ID: mdl-35786412
Temporal muscle thickness (TMT) is a new potential MRI biomarker, which has shown prognostic relevance in neuro-oncology. We aim at investigating the potential prognostic value of TMT in patients with Amyotrophic Lateral Sclerosis (ALS). We retrospectively evaluated 30 ALS patients, whose clinical, Magnetic Resonance Imaging (MRI) and Electrodiagnostic testing (EDX) data were available, in comparison to age-matched 30 healthy subjects. TMT calculated on T1-weighted MR images was significantly lower in ALS patients than in healthy subjects (p < 0.001), correlating with the ALS Functional Rating Scale (FRS) (p:0.018) and compound motor action potential (CMAP) (p:0.012) in the patients group. Multivariate analysis of overall survival (OS) showed that the only parameters that remained significant were TMT (p:0.002, OR 0.45, 95%vCI: 0.28-0.75) and ALS FRS-R (p:0.023, OR: 0.80, 95%CI: 0.67-0.92). TMT seems to be a promising surrogate biomarker of survival and functional status in ALS. Our data deserve further investigations in multicenter and prospective trials.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Amiotrófica Lateral Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Neurol Res Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Amiotrófica Lateral Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Neurol Res Año: 2022 Tipo del documento: Article País de afiliación: Italia
...